<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832971</url>
  </required_header>
  <id_info>
    <org_study_id>AROANG3-2001</org_study_id>
    <nct_id>NCT04832971</nct_id>
  </id_info>
  <brief_title>Study of ARO-ANG3 in Adults With Mixed Dyslipidemia</brief_title>
  <official_title>A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in&#xD;
      participants with mixed dyslipidemia. Participants will receive 2 subcutaneous injections of&#xD;
      ARO-ANG3 or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in Fasting Triglycerides (TG) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting TG Over Time</measure>
    <time_frame>Baseline, up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Non-HDL-C Over Time</measure>
    <time_frame>Baseline, up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Total Apolipoprotein B (ApoB) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Total ApoB Over Time</measure>
    <time_frame>Baseline, up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting Low-density Lipoprotein-Cholesterol (LDL-C) Using Ultracentrifugation at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting LDL-C Using Ultracentrifugation Over Time</measure>
    <time_frame>Baseline, up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Angiopoietin-like Protein 3 (ANGPTL3) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in ANGPTL3 Over Time</measure>
    <time_frame>Baseline, up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) Over Time</measure>
    <time_frame>Baseline, up to Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Plasma Concentrations of ARO-ANG3 Over Time</measure>
    <time_frame>Baseline, up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with AEs and/or SAEs Through Week 36</measure>
    <time_frame>up to Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>ARO-ANG3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARO-ANG3 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Normal Saline (0.9% NaCl)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARO-ANG3</intervention_name>
    <description>2 doses of ARO-ANG3 by subcutaneous (sc) injection</description>
    <arm_group_label>ARO-ANG3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>calculated volume to match active treatment by sc injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Based on medical history, evidence of TG ≥ 150 mg/dL but ≤ 499 mg/dL on more than one&#xD;
             occasion&#xD;
&#xD;
          -  Fasting levels at Screening of LDL-C ≥ 70 mg/dL OR non-HDL-C ≥ 100 mg/dL after at&#xD;
             least 4 weeks of stable optimal statin therapy&#xD;
&#xD;
          -  Mean fasting TG ≥ 150 mg/dL and ≤ 499 mg/dL during Screening collected at two separate&#xD;
             and consecutive visits and at least 7 days apart and not more than 14 days apart&#xD;
&#xD;
          -  Willing to follow diet counseling and maintain a stable diet per Investigator judgment&#xD;
             based on local standard of care&#xD;
&#xD;
          -  Women of childbearing potential on must have a negative pregnancy test, cannot be&#xD;
             breastfeeding, and must be willing to use contraception&#xD;
&#xD;
          -  Women of childbearing potential on hormonal contraceptives must be stable on the&#xD;
             medication for ≥ 2 menstrual cycles prior to Day 1&#xD;
&#xD;
          -  Willing to provide written informed consent and to comply with study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use or use within 365 days from Day 1 of any hepatocyte targeted siRNA or&#xD;
             antisense oligonucleotide molecule&#xD;
&#xD;
          -  Active pancreatitis within 12 weeks prior to Day 1&#xD;
&#xD;
          -  Any planned bariatric surgery or similar procedures to induce weight loss from consent&#xD;
             to end of study&#xD;
&#xD;
          -  Acute coronary syndrome event within 24 weeks of Day 1&#xD;
&#xD;
          -  Major surgery within 12 weeks of Day 1&#xD;
&#xD;
          -  Planned coronary intervention (e.g., stent placement or heart bypass) during the study&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV),&#xD;
             seropositive for Hepatitis C (HCV)&#xD;
&#xD;
          -  Uncontrolled hypothyroidism or hyperthyroidism&#xD;
&#xD;
          -  Hemorrhagic stroke within 24 weeks of Day 1&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Current diagnosis of nephrotic syndrome&#xD;
&#xD;
          -  Systemic use of corticosteroids or anabolic steroids within 4 weeks prior to Day 1 or&#xD;
             planned use during the study&#xD;
&#xD;
          -  Malignancy within the last 2 years prior to date of consent requiring systemic&#xD;
             treatment (some exceptions apply)&#xD;
&#xD;
        Note: additional inclusion/exclusion criteria may apply per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>626-304-3400</phone>
    <email>AROANG3@arrowheadpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Benza</last_name>
      <phone>702-645-4156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Sinai</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1G 3Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Québec</city>
        <zip>H7T2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auckland</city>
        <zip>0626</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <zip>3200</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

